Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation

키워드

참고문헌 (135)

1. Bate SL, "Cytomegalovirus seroprevalence in the United States : the national health and nutrition examination surveys, 1988-2004", Clin Infect Dis, 50, pp.1439~1447 (2010)
2. Choi R, "Seroprevalence of CMV IgG and IgM in Korean women of childbearing age", J Clin Lab Anal, 35, pp.e23716~ (2021)
3. Choi SR, "Changes in cytomegalovirus seroprevalence in Korea for 21 years : a single center study", Pediatr Infect Vaccine, 25, pp.123~131 (2018)
4. Wang C, "Cytomegalovirus IgM seroprevalence among women of reproductive age in the United States", PLoS One, 11, pp.e0151996~ (2016)
5. Odland ML, "Changing patterns of cytomegalovirus seroprevalence among pregnant women in Norway between 1995 and 2009 examined in the Norwegian Mother and Child Cohort Study and two cohorts from Sor-Trondelag County : a cross-sectional study", BMJ Open, 3, pp.e003066~ (2013)
6. La Y, "Human cytomegalovirus seroprevalence and titres in solid organ transplant recipients and transplant donors in Seoul, South Korea", BMC Infect Dis, 19, pp.948~ (2019)
7. Ljungman P, "Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials", Clin Infect Dis, 64, pp.87~91 (2017)
8. Lowance D, "Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group", N Engl J Med, 340, pp.1462~1470 (1999)
9. "Lancet", 1997, 1729~1733
10. Wreghitt TG, "Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients", Transpl Int, 12, pp.254~260 (1999)
11. Lee YM, "Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients", Transpl Infect Dis, 16, pp.397~402 (2014)
12. Ko EJ, "Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy", Korean J Intern Med, 34, pp.375~382 (2019)
13. Kim T, "Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy", Korean J Intern Med, 31, pp.961~970 (2016)
14. Kim SJ, "Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation", J Clin Med, 9, pp.1320~ (2020)
15. Kang R, "Postoperative hyperglycemia may negatively impact cytomegalovirus infection in seropositive liver transplant recipients : a retrospective cohort study", Transpl Int, 33, pp.68~75 (2020)
16. Kwak SH, "Risk factors for cytomegalovirus reactivation in lung transplant recipients", Lung, 198, pp.829~838 (2020)
17. Kim MJ, "Cytomegalovirus infection in pediatric renal transplant recipients : a single center experience", Child Kidney Dis, 21, pp.75~80 (2017)
18. Kim JM, "Oral valganciclovir as a preemptive treatment for cytomegalovirus(CMV)infection in CMV-seropositive liver transplant recipients", PLoS One, 10, pp.e0123554~ (2015)
19. Arthurs SK, "Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation", Clin Infect Dis, 46, pp.840~846 (2008)
20. Kliem V, "Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir : results of a randomized clinical trial", Am J Transplant, 8, pp.975~983 (2008)
21. Witzke O, "Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients : 1-year results of a randomized clinical trial", Transplantation, 93, pp.61~68 (2012)
22. Zamora MR, "Controversies in lung transplantation : management of cytomegalovirus infections", J Heart Lung Transplant, 21, pp.841~849 (2002)
23. Potena L, "Cytomegalovirus-associated allograft rejection in heart transplant patients", Curr Opin Infect Dis, 20, pp.425~431 (2007)
24. Munoz-Price LS, "The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients", Clin Infect Dis, 39, pp.1293~1299 (2004)
25. George MJ, "The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients", Am J Med, 103, pp.106~113 (1997)
26. Beam E, "Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis", Clin Transplant, 30, pp.270~278 (2016)
27. Razonable RR, "Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice", Clin Transplant, 33, pp.e13512~ (2019)
28. Kotton CN, "The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 102, pp.900~931 (2018)
29. "UK guideline on prevention and management of cytomegalovirus infection and disease following solid organ transplantation" (2022)[URL]
30. Pilmore H, "KHA-CARI guideline : cytomegalovirus disease and kidney transplantation", Nephrology(Carlton), 16, pp.683~687 (2011)
31. Guyatt GH, "GRADE : an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
32. Guyatt GH, "Going from evidence to recommendations", BMJ, 336, pp.1049~1051 (2008)
33. Atkins D, "Grading quality of evidence and strength of recommendations", BMJ, 328, pp.1490~ (2004)
34. Girmenia C, "Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant : a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies", Clin Transplant, 33, pp.e13666~ (2019)
35. Portela D, "OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation", J Infect Dis, 171, pp.1014~1018 (1995)
36. Ambrose T, "Cytomegalovirus infection and rates of antiviral resistance following intestinal and multivisceral transplantation", Transplant Proc, 48, pp.492~496 (2016)
37. Malvezzi P, "Use of Everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant", Exp Clin Transplant, 14, pp.361~366 (2016)
38. Pascual J, "Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients", Transpl Infect Dis, 18, pp.819~831 (2016)
39. Razonable RR, "Cytomegalovirus in solid organ transplantation", Am J Transplant, 13(Suppl 4), pp.93~106 (2013)
40. Kotton CN, "Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation", Transplantation, 96, pp.333~360 (2013)
41. Fernández-Ruiz M, "Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients : predictive value of the immediate post-transplant assessment", Clin Microbiol Infect, 25, pp.381~ (2019)
42. Fishman JA, "Infection in organ-transplant recipients", N Engl J Med, 338, pp.1741~1751 (1998)
43. Preiksaitis JK, "The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody(1984 to 1996) : experience at a single Canadian center", Transfusion, 42, pp.396~402 (2002)
44. Jarque M, "Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation : a prospective, interventional, multicenter clinical trial", Clin Infect Dis, 71, pp.2375~2385 (2020)
45. Kim SH, "Clinical applications of interferon-γ releasing assays for cytomegalovirus to differentiate cytomegalovirus disease from bystander activation : a pilot proof-of-concept study", Korean J Intern Med, 32, pp.900~909 (2017)
46. Kim T, "Diagnostic usefulness of the cytomegalovirus(CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant", Korean J Intern Med, 35, pp.438~448 (2020)
47. Mihm J, "Immune-based guidance of foscarnet treatment duration in a transplant recipient with ganciclovir-resistant cytomegalovirus infection", J Clin Virol, 82, pp.5~8 (2016)
48. Meesing A, "Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients", Transplantation, 103, pp.832~838 (2019)
49. Paya C, "Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients", Am J Transplant, 4, pp.611~620 (2004)
50. Hodson EM, "Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants : a systematic review of randomised controlled trials", Lancet, 365, pp.2105~2115 (2005)
51. Kalil AC, "Meta-analysis : the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients", Ann Intern Med, 143, pp.870~880 (2005)
52. Humar A, "A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients", Am J Transplant, 5, pp.1462~1468 (2005)
53. Hodson EM, "Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients", Cochrane Database Syst Rev, (2), pp.CD003774~ (2013)
54. Raval AD, "Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients : A systematic review of randomized controlled trials", Transplant Rev(Orlando), 35, pp.100587~ (2021)
55. Santos CA, "Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation", Transplantation, 98, pp.187~194 (2014)
56. Razonable RR, "Allograft rejection predicts the occurrence of late-onset cytomegalovirus(CMV)disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir", J Infect Dis, 184, pp.1461~1464 (2001)
57. Snydman DR, "Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients", N Engl J Med, 317, pp.1049~1054 (1987)
58. Khoury JA, "Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients", Am J Transplant, 6, pp.2134~2143 (2006)
59. Reischig T, "Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation", Am J Transplant, 8, pp.69~77 (2008)
60. Witzke O, "Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients : 1-year results of a randomized clinical trial", Transplantation, 93, pp.61~68 (2012)
61. Spinner ML, "Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes", Transplantation, 90, pp.412~418 (2010)
62. Reischig T, "Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation", J Am Soc Nephrol, 23, pp.1588~1597 (2012)
63. Owers DS, "Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients", Cochrane Database Syst Rev, 2013, pp.CD005133~ (2013)
64. Florescu DF, "A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant", Clin Infect Dis, 58, pp.785~803 (2014)
65. Mumtaz K, "Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation : a systematic review and meta-analysis", Am J Transplant, 15, pp.472~481 (2015)
66. Singh N, "Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors : a randomized clinical trial", JAMA, 323, pp.1378~1387 (2020)
67. Atabani SF, "Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy", Am J Transplant, 12, pp.2457~2464 (2012)
68. Paraskeva M, "Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome", Am J Transplant, 11, pp.2190~2196 (2011)
69. Palmer SM, "Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation : a randomized, controlled trial", Ann Intern Med, 152, pp.761~769 (2010)
70. Madan RP, "A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients", Transplantation, 87, pp.1318~1324 (2009)
71. Lin A, "Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients", J Pediatric Infect Dis Soc, 1, pp.278~283 (2012)
72. Lee SO, "Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients", Transpl Infect Dis, 12, pp.31~37 (2010)
73. Zuk DM, "An international survey of cytomegalovirus management practices in lung transplantation", Transplantation, 90, pp.672~676 (2010)
74. Huh K, "Nationwide survey of infection prevention protocols in solid organ transplantation in South Korea", Korean J Transplant, 36, pp.212~220 (2022)
75. Conti DJ, "Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients", Arch Surg, 130, pp.1217~1221 (1995)
76. Hibberd PL, "Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial", Ann Intern Med, 123, pp.18~26 (1995)
77. Humar A, "Extended valganciclovir prophylaxis in D+", R-kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease : two-year results of the IMPACT study, 2010, pp.90, 1427~1431
78. Schoeppler KE, "Late-onset cytomegalovirus(CMV)in lung transplant recipients : can CMV serostatus guide the duration of prophylaxis?", Am J Transplant, 13, pp.376~382 (2013)
79. Couchoud C, "Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation", Cochrane Database Syst Rev, (2), pp.CD001320~ (2000)
80. Rubin RH, "Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis", Transpl Infect Dis, 2, pp.112~117 (2000)
81. Le Page AK, "International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines", Transplantation, 95, pp.1455~1460 (2013)
82. Levitsky J, "A survey of CMV prevention strategies after liver transplantation", Am J Transplant, 8, pp.158~161 (2008)
83. Humar A, "The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients", Am J Transplant, 10, pp.1228~1237 (2010)
84. "Highlights of prescribing information (Valcyte®)" (2021)[URL]
85. Kalil AC, "Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation : direct and indirect treatment comparison meta-analysis", Clin Infect Dis, 52, pp.313~321 (2011)
86. Chamberlain CE, "Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients", Am J Transplant, 8, pp.1297~1302 (2008)
87. Pescovitz MD, "Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients", Antimicrob Agents Chemother, 44, pp.2811~2815 (2000)
88. Stevens DR, "Increased risk of breakthrough infection among cytomegalovirus donor-positive", recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis, 2015, pp.17, 163~173
89. Gabardi S, "Evaluation of low-versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients", Transplantation, 99, pp.1499~1505 (2015)
90. Heldenbrand S, "Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive(D+", R+)renal transplant recipients, 2016, pp.18, 904~912
91. Hwang SD, "Effect of low-dose vs standard-dose valganciclovir in the prevention of cytomegalovirus disease in kidney transplantation recipients : a systemic review and meta-analysis", Transplant Proc, 50, pp.2473~2478 (2018)
92. Xin W, "Effectiveness of valganciclovir 900mg versus 450mg for cytomegalovirus prophylaxis in renal transplantation : a systematic review and meta-analysis", J Pharm Pharm Sci, 20, pp.168~183 (2017)
93. Reischig T, "Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection", Transplantation, 79, pp.317~324 (2005)
94. Pavlopoulou ID, "A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients", Clin Microbiol Infect, 11, pp.736~743 (2005)
95. Reischig T, "Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation", Clin J Am Soc Nephrol, 10, pp.294~304 (2015)
96. Snydman DR, "Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial", Ann Intern Med, 119, pp.984~991 (1993)
97. Zamora MR, "Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation", Am J Transplant, 4, pp.1635~1642 (2004)
98. Valantine HA, "Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation : a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone", Transplantation, 72, pp.1647~1652 (2001)
99. Snydman DR, "Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ : a multicenter, open-label study", Transplant Proc, 33, pp.2571~2575 (2001)
100. Bonaros N, "CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients : a meta-analysis", Clin Transplant, 22, pp.89~97 (2008)
101. Hodson EM, "Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients", Cochrane Database Syst Rev, (2), pp.CD005129~ (2007)
102. Marty FM, "Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation", N Engl J Med, 377, pp.2433~2444 (2017)
103. Limaye AP, "Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients : a randomized clinical trial", JAMA, 330, pp.33~42 (2023)
104. Maertens J, "Maribavir for preemptive treatment of cytomegalovirus reactivation", N Engl J Med, 381, pp.1136~1147 (2019)
105. Marty FM, "A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation", Biol Blood Marrow Transplant, 25, pp.369~381 (2019)
106. "Highlights of prescribing information (Ganciclovir injection)" (2017)[URL]
107. Varela-Fascinetto G, "Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and", or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease, 2017, pp.21, e12833~
108. Hashim F, "Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation", Open Urol Nephrol J, 7(Suppl 2 M7), pp.152~157 (2014)
109. Engelmann C, "Prevention and management of CMV infections after liver transplantation : current practice in German transplant centers", J Clin Med, 9, pp.2352~ (2020)
110. Jaksch P, "Cytomegalovirus prevention in high-risk lung transplant recipients : comparison of 3-vs 12-month valganciclovir therapy", J Heart Lung Transplant, 28, pp.670~675 (2009)
111. Finlen Copeland CA, "Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation : a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial", J Heart Lung Transplant, 30, pp.990~996 (2011)
112. Wiita AP, "Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis", Transpl Infect Dis, 14, pp.248~258 (2012)
113. Boeckh M, "Quantitation of cytomegalovirus : methodologic aspects and clinical applications", Clin Microbiol Rev, 11, pp.533~554 (1998)
114. Kusne S, "Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy : a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients", Transplantation, 68, pp.1125~1131 (1999)
115. Hodinka RL, "Manual of clinical microbiology", pp.1770~1796 (2019), Press
116. Razonable RR, "Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation", Clin Microbiol Rev, 26, pp.703~727 (2013)
117. Dioverti MV, "Comparison of standardized cytomegalovirus(CMV)viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease", Open Forum Infect Dis, 4, pp.ofx143~ (2017)
118. Sanghavi SK, "Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients", J Clin Virol, 42, pp.335~342 (2008)
119. Cariani E, "Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus(HCMV)management in immunocompromised patients", BMC Infect Dis, 7, pp.138~ (2007)
120. Gerna G, "Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients : a randomized study", Antivir Ther, 12, pp.63~72 (2007)
121. Kraft CS, "Interpreting quantitative cytomegalovirus DNA testing : understanding the laboratory perspective", Clin Infect Dis, 54, pp.1793~1797 (2012)
122. Hirsch HH, "An international multicenter performance analysis of cytomegalovirus load tests", Clin Infect Dis, 56, pp.367~373 (2013)
123. Emery VC, "Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation", Lancet, 355, pp.2032~2036 (2000)
124. Vinuesa V, "Would kinetic analyses of plasma cytomegalovirus DNA load help to reach consensus criteria for triggering the initiation of preemptive antiviral therapy in transplant recipients?", Clin Infect Dis, 63, pp.1533~1535 (2016)
125. Mattes FM, "Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir", J Infect Dis, 191, pp.89~92 (2005)
126. Asberg A, "Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients", Am J Transplant, 9, pp.1205~1213 (2009)
127. Lisboa LF, "The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response", Transplantation, 91, pp.231~236 (2011)
128. Dioverti MV, "Treatment of cytomegalovirus infection and disease pre-and post-quantitative nucleic acid test standardization : does use of a more sensitive assay lead to longer treatment duration?", Clin Transplant, 30, pp.154~160 (2016)
129. Paya CV, "Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients : a randomized, placebo-controlled trial", J Infect Dis, 185, pp.854~860 (2002)
130. Razonable RR, "Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir", J Infect Dis, 187, pp.1801~1808 (2003)
131. Thompson G, "Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia", Pathology, 50, pp.554~561 (2018)
132. Schachtner T, "CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor", Transplantation, 101, pp.e315~e325 (2017)
133. Rogers R, "Clinical experience with a novel assay measuring cytomegalovirus(CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events", BMC Infect Dis, 20, pp.58~ (2020)
134. Kumar D, "An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation", Am J Transplant, 17, pp.2468~2473 (2017)
135. Chen J, "Kinetics of IgG antibody to cytomegalovirus(CMV)after birth and seroprevalence of anti-CMV IgG in Chinese children", Virol J, 9, pp.304~ (2012)

관련 논문AI추천